<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03919344</url>
  </required_header>
  <id_info>
    <org_study_id>APHP 180442</org_study_id>
    <nct_id>NCT03919344</nct_id>
  </id_info>
  <brief_title>Pathophysiological Study of CSA in Adults With pLVEF</brief_title>
  <acronym>PHENOSAX</acronym>
  <official_title>Pathophysiological Study of Central Sleep Apnea in Adults With Preserved LVEF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sleep apnea is classically divided into obstructive and central apnea, according to the&#xD;
      persistence or otherwise of respiratory movements and the existence or not of pharyngeal&#xD;
      collapse during apnea. However, there is evidence to suggest that some mechanisms are common&#xD;
      to both types of apnea. Although the pathophysiology of obstructive apnea has been the&#xD;
      subject of much work and now seems fairly well known, there is much less data on central&#xD;
      apnea. These apneas can occur in different comorbid contexts. They are more frequently&#xD;
      present in patients with heart failure, regardless of the etiology, and are associated with&#xD;
      an adverse prognosis. The investigators hypothesize that the physiopathology of adult central&#xD;
      apnea syndrome involves, in addition to ventilatory control abnormalities, upper airway&#xD;
      abnormalities (VAS). The objective is to study the pathophysiology of central SAS, by first&#xD;
      comparing the collapse of VAS of central apneic patients to those of patients with simple&#xD;
      snoring or obstructive sleep apnea. In a second step, the investigators will analyze the&#xD;
      cardiorespiratory coupling and will establish a map of the respiratory neural network in&#xD;
      patients with central apnea. The investigators will focus their study on patients with&#xD;
      central SAS (with preserved systolic heart function) due to the epidemiology of SAS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A non-randomized case-control comparative monocentric physiopathology study with 3 parallel&#xD;
      groups (one group of cases and two control groups) matched for age and body mass index&#xD;
      (individual 1: 1: 1 match), to evaluate changes in the collapse of VAS in central apnea&#xD;
      (&quot;central SAS case&quot;), compared to subjects without central apnea (&quot;obstructive SAS&quot; and&#xD;
      &quot;single snoring&quot;).&#xD;
&#xD;
      Primary objective : Evaluation of changes in upper airway collapse in patients with central&#xD;
      sleep apnea syndrome with preserved LVEF heart failure (&quot;central SAS case&quot;), compared with&#xD;
      snoring subjects free from sleep apnea syndrome (&quot;Simple snoring witnesses&quot;)&#xD;
&#xD;
      Secondary objectives :&#xD;
&#xD;
        -  Study the collapsibility of VAS according to the type of apnea (&quot;central SAS case&quot;&#xD;
           versus &quot;obstructive SAS case&quot;).&#xD;
&#xD;
        -  To study the association between the collapsibility of VAS and the global and central&#xD;
           apnea-hypopnoea index (IAH).&#xD;
&#xD;
        -  Study the association between the type of disorder (&quot;central SAS case&quot; versus &quot;simple&#xD;
           snoring controls&quot;, &quot;central SAS case&quot; versus &quot;obstructive SAS controls&quot;) and&#xD;
           cardiorespiratory coupling.&#xD;
&#xD;
        -  Study the association between the type of disorder (&quot;central SAS case&quot; versus &quot;simple&#xD;
           snoring controls&quot;, &quot;central SAS case&quot; versus &quot;obstructive SAS controls&quot;) and the CO2&#xD;
           response slope.&#xD;
&#xD;
        -  Establish a map of the respiratory neural network in patients with central SAS with&#xD;
           preserved ejection fraction.&#xD;
&#xD;
        -  Study the association between the volumes in acoustic pharyngometry and the values of&#xD;
           the Pcrit&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2, 2021</start_date>
  <completion_date type="Anticipated">February 2, 2025</completion_date>
  <primary_completion_date type="Anticipated">February 2, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Upper airway collapsibility is assessed by Pcrit value in central leep apnea and snoring</measure>
    <time_frame>1 day</time_frame>
    <description>Pressure values of VAS (Pcrit) in patients in the &quot;Central SAS&quot; group and in the &quot;Obstructive SAS&quot; group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Upper airway collapsibility is assessed by Pcrit value in central and obstructive sleep apnea</measure>
    <time_frame>1 day</time_frame>
    <description>Pcrit value in cm H20 in the obstructive SAS group vs. central SAS group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The association between Pcrit (cm H20) and Apnea-Hypopnoea Index (events/h)</measure>
    <time_frame>1 day</time_frame>
    <description>The association between Pcrit (cm H20) and Global and Central Apnea-Hypopnoea Index (events/h)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemosensitivity in central sleep apnea is assessed by CO2 response test</measure>
    <time_frame>1 day</time_frame>
    <description>CO2 response slope (mL/min/mmHg) in CO2 response test via rebrething method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiorespiratory coupling in central sleep apnea is assessed by RR measurment (mm on EKG)</measure>
    <time_frame>1 day</time_frame>
    <description>Parameters of cardiorespiratory coupling to polysomnography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neural network modifications in sleep apnea are assessed by frequency couplage indice</measure>
    <time_frame>1 day</time_frame>
    <description>Respiratory neural network mapping in patients with central SAS with preserved ejection fraction through high density mapping</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume and collapsibility characteristics in acoustic pharyngometry in the different groups</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Central Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Central SAS cases</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with central apnea</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obstructive SAS controls</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with moderate to severe obstructive apnea (apnea-hypopnoea index ≥ 15 / h)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Snorers controls</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Snorers controls : Patients with snoring, with or without mild obstructive apneas (index of apnea-hypopneas &lt;15 / h)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Critical airway closure pressure (Pcrit) measurment</intervention_name>
    <description>Pcrit is measured in awake patient, by applying a gradually decreasing pressure through a nasal NIV mask. Pcrit is defined as the pressure inducing airflow cessation in upper airway</description>
    <arm_group_label>Central SAS cases</arm_group_label>
    <arm_group_label>Obstructive SAS controls</arm_group_label>
    <arm_group_label>Snorers controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Acoustic pharyngometry</intervention_name>
    <description>Acoustic pharyngometry will assess the volume of the pharynx and determine if there is an obstacle in the upper airways.</description>
    <arm_group_label>Central SAS cases</arm_group_label>
    <arm_group_label>Obstructive SAS controls</arm_group_label>
    <arm_group_label>Snorers controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>High density surface electroencephalogram neural mapping</intervention_name>
    <description>Mapping of the respiratory neural network will allow us to study the areas of the brain activated during breathing</description>
    <arm_group_label>Central SAS cases</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male patient&#xD;
&#xD;
          -  Age ≥18 years and ≤85 years&#xD;
&#xD;
          -  With preserved LVEF heart failure (defined as LVEF ≥ 45% on ultrasound, MRI or&#xD;
             isotopic ventriculography)&#xD;
&#xD;
          -  Central SAS Group: Central to severe sleep apnea syndrome, defined by an&#xD;
             apnea-hypopnoea index (IAH) greater than 15 per hour, of which at least 30% are&#xD;
             central events;&#xD;
&#xD;
          -  Obstructive SAS group: Moderate to severe obstructive sleep apnea syndrome, defined by&#xD;
             an apnea-hypopnoea index (IAH) greater than 15 per hour, with a central event&#xD;
             proportion of less than 30%&#xD;
&#xD;
          -  Group &quot;snoring&quot;: absence of sleep apnea syndrome or mild sleep apnea syndrome (IAH &lt;15&#xD;
             / h) in polysomnography, and presence of snoring on at least 30% of the night of&#xD;
             recording.&#xD;
&#xD;
          -  Free, informed and written consent&#xD;
&#xD;
          -  Patient affiliated to a social security scheme (beneficiary or beneficiary)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Impossibility of giving the subject informed information&#xD;
&#xD;
          -  Participation in a research protocol involving the human person in the previous months&#xD;
             if an exclusion directive is given in this protocol&#xD;
&#xD;
          -  Use of respiratory or sedative depressant drugs, systemic corticosteroid therapy&#xD;
&#xD;
          -  Impaired systolic function (defined by LVEF &lt;45% in ultrasound, MRI or isotopic&#xD;
             ventriculography)&#xD;
&#xD;
          -  Unstable cardiovascular disease (cardiovascular event of less than one month)&#xD;
&#xD;
          -  Recent surgery of the ENT sphere (less than 6 months)&#xD;
&#xD;
          -  Central neurological pathology known&#xD;
&#xD;
          -  Known, severe respiratory pathology (severity left to the investigator's discretion)&#xD;
&#xD;
          -  Renal insufficiency (creatinine clearance &lt;60 mL / min) or severe hepatic impairment&#xD;
&#xD;
          -  Primary or secondary hemostasis disorder&#xD;
&#xD;
          -  Patient on anticoagulant (antivitamin K, direct oral anticoagulant, heparin and&#xD;
             related). Antiplatelet agents are allowed.&#xD;
&#xD;
          -  Psychiatric pathology according to DSM-V criteria, unbalanced&#xD;
&#xD;
          -  Pulsed saturation with oxyhemoglobin &lt;88% at rest, on awakening&#xD;
&#xD;
          -  Allergy to lidocaine&#xD;
&#xD;
          -  Patient under tutorship or curatorship&#xD;
&#xD;
          -  Failure to perform a prior medical examination&#xD;
&#xD;
          -  Tympanic perforation&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Pia D'ORTHO, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie-Pia D'ORTHO, Professor</last_name>
    <phone>(33) 01 40 25 84 01</phone>
    <email>marie-pia.dortho@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Justine FRIJA MASSON, Doctor</last_name>
    <phone>(33) 01 40 25 84 01</phone>
    <email>justine.frija@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Bichat-Claude Bernard</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Pia D'ORTHO, Professor</last_name>
      <phone>(33) 01 40 25 84 01</phone>
      <email>marie-pia.dortho@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Justine FRIJA MASSON, Doctor</last_name>
      <phone>(33) 01 40 25 84 01</phone>
      <email>justine.frija@aphp.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 12, 2019</study_first_submitted>
  <study_first_submitted_qc>April 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2019</study_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Central</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

